The Argentine Chamber of Medicinal Specialties (CAEME) represents 41 companies, but each associated laboratory will exercise the power to individually adhere to the initiative.
During the first quarter of the year, the cut in the flow of funds to organizations and hospitals was evident, which had a significant impact on firms in the health sector and in the midst of very high inflation. Just days after his inauguration, the president Javier Milei announced that the prepaid fees would move without official intervention, but just four months later, it was forced to regulate them and is on the verge of taking the issue to court. In the midst of this, The zero deficit plan acquired a dizzying paceand public health was not one of the sectors that emerged unscathed from these movements.
According to the budget execution of the first quarter, The Health item represented only 3.8% of the total expenditurewhich marked a decrease of 35% compared to the same period of the previous year, totaling $572,999 million, according to the latest report by the consulting firm Center for Political Economy (CEPA).
CAEME freezes drug prices for 30 days
In this context, the Argentine Chamber of Medicinal Specialties (CAEME), which represents 41 pharmaceutical innovation companies that They research, develop and market medicines in the countryexpressed his willingness to accompany the measures aimed at strengthening the Argentine health system, freezing drug prices for a period of 30 daysas of today, in line with the policy of stabilizing the variables of the Argentine economy.
The entity, which brings together 41 laboratories mainly with foreign capital, but leaves each firm the power to join the initiative. Some of the laboratories that are part of Caeme are: Abbot, Abbvie, Alcon, Amgen, Astellas, AstraZeneca, Bausch+Lomb, Bayer, Merk, GSK, Roche, Sanofi, MSD, Lilly, Novartis, among others.
Based on the above, each associated laboratory will exercise the power to individually adhere to this initiative.
“CAEME reiterates its commitment to contribute and promote timely and equitable access by patients to innovative medicines and treatments within a framework of sustainability and transparency,” the statement concludes.
Source: Ambito
